comparemela.com

Latest Breaking News On - Focus area approach - Page 1 : comparemela.com

U S FDA ACKNOWLEDGES ASTELLAS RESUBMISSION OF BIOLOGICS LICENSE APPLICATION FOR ZOLBETUXIMAB AND SETS NEW ACTION DATE

/PRNewswire/ Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the U.S. Food and Drug Administration (FDA).

United statesUnited kingdomMoitreyee chatterjee kishoreNaoki okamuraRare diseases information centerTranslational sciencesAmerican cancer societyJapan ministry of healthNational institutes of health centerPrnewswire astellas pharma incNational cancer instituteAmerican society of clinical oncologyEnd results programDrug administrationOncology developmentAstellas pharma inc

Astellas Announces a Collaboration with YASKAWA to Create an Innovative Cell Therapy Ecosystem through the Integration of Pharmaceutical and Robotics Technologies

- Focuses on digitizing cell manufacturing processes through robotics technology TOKYO, May 21, 2024 /PRNewswire/ Astellas Pharma Inc. today announced that it signed a memorandum of.

Naoki okamuraAstellas pharma incPrnewswire astellas pharma incSafety of products including pharmaceuticalsRobotic biology instituteMedical deviceAstellas pharmaCell therapy platform combining roboticsMedical device actSecuring qualityProducts including pharmaceuticalsFocus area approach

Astellas Announces A Collaboration With YASKAWA To Create An Innovative Cell Therapy Ecosystem Through The Integration Of Pharmaceutical And Robotics

- Focuses on digitizing cell manufacturing processes through robotics technologyTOKYO, May 21, 2024 /PRNewswire/ Astellas Pharma Inc. (

Naoki okamuraRobotic biology institutePrnewswire astellas pharma incAstellas pharma incSafety of products including pharmaceuticalsMedical deviceAstellas pharmaCell therapy platform combining roboticsMedical device actSecuring qualityProducts including pharmaceuticalsFocus area approach

Astellas Announces a Collaboration with YASKAWA to Create an Innovative Cell Therapy Ecosystem through the Integration of Pharmaceutical and Robotics Technologies - Astellas Pharma (OTC:ALPMY)

- Focuses on digitizing cell manufacturing processes through robotics technology TOKYO, May 21, 2024 /PRNewswire/ Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced

Naoki okamuraAstellas pharma incSafety of products including pharmaceuticalsRobotic biology institutePrnewswire astellas pharma incMedical deviceAstellas pharmaCell therapy platform combining roboticsMedical device actSecuring qualityProducts including pharmaceuticalsFocus area approach

Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology

- Leverages Poseida s proprietary allogeneic CAR-T platform to develop innovative convertibleCAR® programs targeting solid tumors - TOKYO and SAN DIEGO, May 1, 2024 /PRNewswire/ Astellas.

Xyphos biosciencesAstellas pharmaKristin yaremaNaoki okamuraAdam pearsonAstellas companyPoseida therapeutics incExchange commissionXyphos biosciences incAreas of interest astellas pharma incAstellas pharma incPoseida therapeuticsChimeric antigen receptorChief strategy officerPrimary focusFocus area approach

vimarsana © 2020. All Rights Reserved.